There is higher risk for cardiovascular complications during delivery in pregnant patients with psoriasis compared with patients without psoriasis.

Tralokinumab use in patients with head and neck atopic dermatitis was associated with sustained improvements with up to 4 years of treatment.

Treatments for COPD, psoriasis, and neuroendocrine tumors, as well as a next-generation COVID-19 vaccine are under review.

An increased risk of both invasive and superficial fungal infections was observed among patients who received TNF-α inhibitors for various conditions.